184 related articles for article (PubMed ID: 27711942)
1. Reversible Valproic Acid-Induced Parkinsonism and Cognitive Impairment in an Elderly Patient With Bipolar Disorder I.
Hassamal S; Waller S; Reese K; Testa C
Turk Psikiyatri Derg; 2016; 27(3):213-217. PubMed ID: 27711942
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid-induced parkinsonism in the elderly: a comprehensive review of the literature.
Mahmoud F; Tampi RR
Am J Geriatr Pharmacother; 2011 Dec; 9(6):405-12. PubMed ID: 21993183
[TBL] [Abstract][Full Text] [Related]
3. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases.
Masmoudi K; Gras-Champel V; Masson H; Andréjak M
Pharmacopsychiatry; 2006 Jan; 39(1):9-12. PubMed ID: 16453247
[TBL] [Abstract][Full Text] [Related]
4. Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine.
De Dios C; Fudio S; Lorenzo A
J Clin Pharm Ther; 2011 Jun; 36(3):430-2. PubMed ID: 21545624
[TBL] [Abstract][Full Text] [Related]
5. Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.
Patel N; Landry KB; Fargason RE; Birur B
Psychopharmacol Bull; 2017 Jan; 47(1):40-44. PubMed ID: 28138203
[TBL] [Abstract][Full Text] [Related]
6. Valproate-associated hyperammonemic encephalopathy.
Wadzinski J; Franks R; Roane D; Bayard M
J Am Board Fam Med; 2007; 20(5):499-502. PubMed ID: 17823470
[TBL] [Abstract][Full Text] [Related]
7. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?
Haymond J; Ensom MH
Ther Drug Monit; 2010 Feb; 32(1):19-29. PubMed ID: 19901867
[TBL] [Abstract][Full Text] [Related]
8. [A case of Parkinsonian syndrome, cognitive impairment and hyperammonemia induced by divalproate sodium prescribed for bipolar disorder].
Ricard C; Martin K; Tournier M; Bégaud B; Verdoux H
Encephale; 2005; 31(1 Pt 1):98-101. PubMed ID: 15971646
[TBL] [Abstract][Full Text] [Related]
9. Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate.
Senturk V; Goker C; Bilgic A; Olmez S; Tugcu H; Oncu B; Atbasoglu EC
Bipolar Disord; 2007 Jun; 9 Suppl 1():136-44. PubMed ID: 17543032
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
Langosch JM; Drieling T; Biedermann NC; Born C; Sasse J; Bauer H; Walden J; Bauer M; Grunze H
J Clin Psychopharmacol; 2008 Oct; 28(5):555-60. PubMed ID: 18794653
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder.
Redden L; DelBello M; Wagner KD; Wilens TE; Malhotra S; Wozniak P; Vigna NV; Greco N; Kovacs X; Abi-Saab W; Saltarelli M;
J Child Adolesc Psychopharmacol; 2009 Feb; 19(1):83-9. PubMed ID: 19232026
[TBL] [Abstract][Full Text] [Related]
12. An open-label trial of divalproex in children and adolescents with bipolar disorder.
Wagner KD; Weller EB; Carlson GA; Sachs G; Biederman J; Frazier JA; Wozniak P; Tracy K; Weller RA; Bowden C
J Am Acad Child Adolesc Psychiatry; 2002 Oct; 41(10):1224-30. PubMed ID: 12364844
[TBL] [Abstract][Full Text] [Related]
13. Valproate reversibly reduces neurite outgrowth by human SY5Y neuroblastoma cells.
Qian Y; Zheng Y; Tiffany-Castiglioni E
Brain Res; 2009 Dec; 1302():21-33. PubMed ID: 19766605
[TBL] [Abstract][Full Text] [Related]
14. [Reversible Parkinsonism and cognitive impairment following treatment with valproate].
Toribio-Díaz ME; Morera-Guitart J; Palao-Duarte S
Rev Neurol; 2008 Oct 1-15; 47(7):390-1. PubMed ID: 18841554
[No Abstract] [Full Text] [Related]
15. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature.
Nasrallah HA; Ketter TA; Kalali AH
J Affect Disord; 2006 Oct; 95(1-3):69-78. PubMed ID: 16780960
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome with divalproex in children and adolescents with bipolar disorder.
Henry CA; Zamvil LS; Lam C; Rosenquist KJ; Ghaemi SN
J Child Adolesc Psychopharmacol; 2003; 13(4):523-9. PubMed ID: 14977465
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal management of valproic acid toxicity: a case report and review of the literature.
Al Aly Z; Yalamanchili P; Gonzalez E
Semin Dial; 2005; 18(1):62-6. PubMed ID: 15663767
[TBL] [Abstract][Full Text] [Related]
18. [The influence of mood-normalizing agents on cognitive functions].
Suwalska A; Łojko D; Rybakowski J
Psychiatr Pol; 2001; 35(2):245-56. PubMed ID: 11490889
[TBL] [Abstract][Full Text] [Related]
19. Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment.
Guerrini R; Belmonte A; Canapicchi R; Casalini C; Perucca E
Epilepsia; 1998 Jan; 39(1):27-32. PubMed ID: 9578009
[TBL] [Abstract][Full Text] [Related]
20. Encephalopathy and myoclonus triggered by valproic acid.
Reif A; Leonhard C; Mössner R; Lesch KP; Fallgatter AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):1061-3. PubMed ID: 15380868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
